RenovoRx Statistics

Total Valuation

RenovoRx has a market cap or net worth of $49.74 million. The enterprise value is $35.26 million.

Market Cap	49.74M
Enterprise Value	35.26M

Important Dates

The next estimated earnings date is Tuesday, August 12, 2025, after market close.

Earnings Date	Aug 12, 2025
Ex-Dividend Date	n/a

Share Statistics

RenovoRx has 36.57 million shares outstanding. The number of shares has increased by 124.44% in one year.

Current Share Class	36.57M
Shares Outstanding	36.57M
Shares Change (YoY)	+124.44%
Shares Change (QoQ)	+25.05%
Owned by Insiders (%)	3.33%
Owned by Institutions (%)	12.00%
Float	29.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	149.52
Forward PS	20.96
PB Ratio	3.78
P/TBV Ratio	3.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	146.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.07, with a Debt / Equity ratio of 0.02.

Current Ratio	9.07
Quick Ratio	8.54
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -136.13% and return on invested capital (ROIC) is -95.38%.

Return on Equity (ROE)	-136.13%
Return on Assets (ROA)	-69.73%
Return on Invested Capital (ROIC)	-95.38%
Return on Capital Employed (ROCE)	-81.27%
Revenue Per Employee	$24,000
Profits Per Employee	-$1.02M
Employee Count	10
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +29.52% in the last 52 weeks. The beta is 1.32, so RenovoRx's price volatility has been higher than the market average.

Beta (5Y)	1.32
52-Week Price Change	+29.52%
50-Day Moving Average	1.10
200-Day Moving Average	1.12
Relative Strength Index (RSI)	64.71
Average Volume (20 Days)	238,920

Short Selling Information

The latest short interest is 169,612, so 0.46% of the outstanding shares have been sold short.

Short Interest	169,612
Short Previous Month	262,375
Short % of Shares Out	0.46%
Short % of Float	0.57%
Short Ratio (days to cover)	0.85

Income Statement

In the last 12 months, RenovoRx had revenue of $240,000 and -$10.16 million in losses. Loss per share was -$0.39.

Revenue	240,000
Gross Profit	146,000
Operating Income	-11.60M
Pretax Income	-8.05M
Net Income	-10.16M
EBITDA	n/a
EBIT	-11.60M
Loss Per Share	-$0.39

Full Income Statement

Balance Sheet

The company has $14.58 million in cash and $283,000 in debt, giving a net cash position of $14.30 million or $0.39 per share.

Cash & Cash Equivalents	14.58M
Total Debt	283,000
Net Cash	14.30M
Net Cash Per Share	$0.39
Equity (Book Value)	13.16M
Book Value Per Share	0.36
Working Capital	14.01M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$10.30 million and capital expenditures -$14,000, giving a free cash flow of -$10.32 million.

Operating Cash Flow	-10.30M
Capital Expenditures	-14,000
Free Cash Flow	-10.32M
FCF Per Share	-$0.28

Full Cash Flow Statement

Margins

Gross Margin	60.83%
Operating Margin	-4,835.00%
Pretax Margin	-4,232.50%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RenovoRx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-124.44%
Shareholder Yield	-124.44%
Earnings Yield	-20.50%
FCF Yield	-20.82%

Analyst Forecast

The average price target for RenovoRx is $7.25, which is 433.09% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$7.25
Price Target Difference	433.09%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	394.31%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RenovoRx has an Altman Z-Score of 0.19 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.19
Piotroski F-Score	1